DNER and neoplasm: Finally, it should be noted that, unfortunately, a recent Phase I clinical trial study based on BAY 1238097 was discontinued due to dose-limiting toxicity in patients [22], indicating that more investigation is needed to explore and identify BET inhibitors with limited side effects that retain anti-tumor efficacy within an acceptable therapeutic window.